Oncolytics Biotech (ONCY) Fundamentals 2026 — Revenue Analysis | SniperIQ
Oncolytics Biotech (ONCY) is a US-listed Healthcare company in Biotechnology with a market capitalization of $83M, trading at $0.83 on the NASDAQ. This SniperIQ fundamentals page covers Oncolytics Biotech's valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Oncolytics Biotech's market cap?
Oncolytics Biotech (ONCY) has a market capitalization of approximately $83M, trading at $0.83 on the NASDAQ. Market cap moves with the live share price.
How profitable is Oncolytics Biotech?
Oncolytics Biotech runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
Does Oncolytics Biotech pay a dividend?
Oncolytics Biotech does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Oncolytics Biotech financially healthy?
Oncolytics Biotech carries a debt-to-equity ratio of -0.10x and a current ratio of 1.38x, with a market beta of 1.09. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Oncolytics Biotech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Oncolytics Biotech (ONCY) the key facts are: market cap $83M, 52-week range 0.77-1.51. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Oncolytics Biotech's full fundamentals live
Get Oncolytics Biotech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.